Skip to main content
SpringerLink
Log in

New antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseases

  • Chapter
Infectious Complications of Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 79))

Abstract

Patients with neoplastic diseases are predisposed to develop invasive fungal infections as the result of impairments host defense, due principally to pharmacological immunosuppression resulting from intensive cytotoxic chemotherapy, ablative radiation therapy, and corticosteroids. Candida spp., Aspergillus spp., and emerging opportunistic fungal pathogens comprise the principal etiological agents of opportunistic mycoses in neutropenic cancer patients. This chapter will review advances in the development of new antifungal drugs and therapeutic strategies for the treatment of life-threatening mycoses in neutropenic hosts.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gold W, Stout HA, Pagona JF, et al. 1955. Amphotericins A & B, antifungal antibiotics produced by a streptomycete. Antibiot Ann, pp 579–586.

    Google Scholar 

  2. Kerridge D. 1986. Mode of action of clinically important antifungal drugs. Adv Microb Physiol 27:1–72.

    PubMed  CAS  Google Scholar 

  3. Palacios J, Serrano R. 1978. Proton permeability induced by polyene antibiotics. A plausible mechanism for their inhibition of maltose fermentation in yeast. Fede Euro Biochem Soci Lett 91:198–201.

    CAS  Google Scholar 

  4. Gale EF. 1986. Nature and development of phenotypic resistance to amphotericin B in Candida albicans. Adv Microb Physiol 27:278–320.

    Google Scholar 

  5. Medoff G, Kobayashi GS. 1980. Strategies in the treatment of systemic fungal infections. N Engl J Med 302:145–155.

    PubMed  CAS  Google Scholar 

  6. Vertut-Croquin A, Bolard J, Chabert M, Gary-Bobo C. 1983. Differences in the interaction of the polyene antibiotic amphotericin B with cholesterol- or ergosterol-containing phospholipid vesicles. A circular dichroism and permeability study. Biochemistry 22:2939–2944.

    PubMed  CAS  Google Scholar 

  7. Sokol-Anderson ML, Brajtburg J, Medoff G. 1986. Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis 154:76–83.

    PubMed  CAS  Google Scholar 

  8. Wilson et al. 191.

    Google Scholar 

  9. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. 1990. Amphotericin B: Current understanding of mechanisms of action. Antimicrob Agents Chemother 34:183–188.

    PubMed  CAS  Google Scholar 

  10. Atkinson AJ Jr, Bennett JE. 1978. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 13:271–276.

    PubMed  Google Scholar 

  11. Benson JM, Nahata MC. 1989. Pharmacokinetics of amphotericin B in children. Antimicrob Agents Chemother 33:1989–1993.

    PubMed  CAS  Google Scholar 

  12. Craven PC, Ludden TM, Drutz DJ, Rogers W, Haegek KA, Skradlant HB. 1979. Excretion pathways of amphotericin B. J Infect Dis 140:329–341.

    PubMed  CAS  Google Scholar 

  13. Starke JR, Mason O, Kramer WG, Kaplan SL. 1987. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis 155:766–774.

    PubMed  CAS  Google Scholar 

  14. Christiansen et al. 1985.

    Google Scholar 

  15. Gallis HQ, Drew RH, Pickard WW. 1990. Amphotericin B: 30 years of clinical experience. Revi Infect Dis 12:308–329.

    CAS  Google Scholar 

  16. Bindschadler DD, Bennett JE. 1969. A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis 120:427–436.

    PubMed  CAS  Google Scholar 

  17. Powderly WG, Granich GG, Herzid GP, Krogstad DJ. 1987. HPLC measurement of amphotericin B serum levels in cancer patients. 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract no. 782, Washington, DC.

    Google Scholar 

  18. Fields BT Jr, Bates JH, Abernathy RS. 1971. Effect of rapid intravenous infusion on serum concentrations of amphotericin B. Appl Microbiol 22:615–617.

    PubMed  Google Scholar 

  19. Polat, 1979.

    Google Scholar 

  20. Utz JP, Garriques IL, Sande MA, Warner JF, Mandell GL, et al. 1975. Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis 132:368–373.

    PubMed  CAS  Google Scholar 

  21. Craven PC, Drutz DJ. 1979. Tissue storage of amphotericin B and amphotericin B methyl ester aspartate. 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract no. 156, Washington, DC.

    Google Scholar 

  22. Adamson PC, Rinaldi MG, Pizzo PA, Walsh TJ. 1989. Amphotericin B in treatment of Candida cholecystitis. Pediatr Infect Dis J 8:408–411.

    PubMed  CAS  Google Scholar 

  23. Reynolds ES, Tomkiewicz ZM, Dammin GJ. 1963. The renal lesion related to amphotericin B treatment for coccidiodomycosis. Med Clin North Am 47:1149–1154.

    PubMed  CAS  Google Scholar 

  24. Daneshmend TK, Warnock DW. 1983. Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 8:17–42.

    PubMed  CAS  Google Scholar 

  25. Walsh TJ, Pizzo PA. 1988. Treatment of systemic fungal infections: Recent progress and current problems. Eur J Clin Microbiol Infect Dis 7:460–475.

    PubMed  CAS  Google Scholar 

  26. Gelfand JA, Kimball K, Burke JF, et al. 1988. Amphotericin B treatment of human mononuclear cells in vitro results in secretion of tumor necrosis factor and interleukin-1. Clin Res 36:456A.

    Google Scholar 

  27. Burks LC, Aisner J, Fortner CL, et al. 1980. Meperidine for the treatment of shaking chills and fever. Arch Intern Med 140:483–484.

    PubMed  CAS  Google Scholar 

  28. Koldin MH, Medoff G. 1983. Antifungal chemotherapy. Pediatr Clin North Am 30:49–61.

    PubMed  CAS  Google Scholar 

  29. Graybill JR. 1988. Systemic fungal infections: Diagnosis and treatment I. Therapeutic agents. Infect Dis Clin North Am 2:805–825.

    PubMed  CAS  Google Scholar 

  30. Maddux MS, Barriere SL. 1980. A review of complications of amphotericin B therapy: Recommendations for prevention and management. Drug Intelli Clin Pharm 14:177–181.

    Google Scholar 

  31. Burgess JL, Birchall R. 1972. Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function. Am J Med 53:77–84.

    PubMed  CAS  Google Scholar 

  32. Sabra R, Branch RA. 1990. Amphotericin B nephrotoxicity. Drug Saf 5:94–108.

    PubMed  CAS  Google Scholar 

  33. Boland et al. 1980.

    Google Scholar 

  34. Cheng et al. 1982.

    Google Scholar 

  35. Branch RA. 1988. Prevention of amphotericin B-induced renal impairment: A review on the use of sodium supplementation. Arch Intern Med 148:2389–2394.

    PubMed  CAS  Google Scholar 

  36. Heidemann HT, Gerkens JF, Spickard WA, Jackson EK, Branch RA. 1983. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 75:476–481.

    PubMed  CAS  Google Scholar 

  37. Wasan KM, Vadiei K, Lopez-Berestein G, Verani RR, Luke DR. 1990. Pentoxifylline in amphotericin B toxicity rat model. Antimicrob Agents Chemother 34:241–244.

    PubMed  CAS  Google Scholar 

  38. Butler WT, Bennett JE, Alling DW, Wertlake PT, Utz JP, Hill GJ III. 1964. Nephrotoxicity of amphotericin B: Early and late effects in 81 patients. Ann Intern Med 61:175–187.

    PubMed  CAS  Google Scholar 

  39. Feely J, Heidemann H, Gerkins J, Roberts LJ, Branch RA. 1981. Sodium depletion enhances nephrotoxicity of amphotericin B. Lancet 1:1422–1423.

    PubMed  CAS  Google Scholar 

  40. Ohnishi A, Ohnishi T, Stevenhead W, Bobinson RD, Branch RA, et al. 1989. Sodium status influences chronic amphotericin B nephrotoxicity in the rat. Antimicrob Agents Chemother 33:1222– 1227.

    PubMed  CAS  Google Scholar 

  41. Branch RA, Jackson EK, Jacqz E, Steen R, Ray WA, et al. 1987. Amphotericin B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline. Klin Wochenschrift 65:500–506.

    CAS  Google Scholar 

  42. Butler WT. 1966. Pharmacology, toxicology and therapeutic usefulness of amphotericin B. JAMA 195:127–131.

    Google Scholar 

  43. Warda, J, Barriere SL. 1985. Amphotericin B nephrotoxicity. Drug Intelli Clin Pharma 19:25–26.

    Google Scholar 

  44. Barton CH, Pahl M, Vaziri ND, Cesario T. 1984. Renal magnesium wasting associated with amphotericin B therapy. Am J Med 77:471–474.

    PubMed  CAS  Google Scholar 

  45. MacGregor RR, Bennett JE, Erslev AJ. 1978. Erythropoietin concentration in amphotericin B-induced anemia. Antimicrob Agents Chemother 14:270–273.

    PubMed  CAS  Google Scholar 

  46. Sarosi GA. 1990. Amphotericin B: Still the ‘gold standard’ for antifungal therapy. Postgrad Med 88:151–166.

    PubMed  CAS  Google Scholar 

  47. Kennedy MS, Deeg HJ, Siegel M, Crowley JJ, Storb R, Thomas ED. 1983. Acute reaction toxicity with combined use of amphotericin B and cyclosporine A after marrow transplantation. Transplantation 35:211–215.

    PubMed  CAS  Google Scholar 

  48. Wright DG, Robichaud KJ, Pizzo PA, Deisseroth AB. 1981. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med 304:1185–1189.

    PubMed  CAS  Google Scholar 

  49. Dana BW, Durie BGM, White RF, Huestis DW. 1981. Concomitant administration of granulocyte transfusions and amphotericin B in neutropenic patients: Absence of significant pulmonary toxicity. Blood 57:90–94.

    PubMed  CAS  Google Scholar 

  50. Roilides E, Walsh TJ, Rubin M, Venzon D, Pizzo PA. 1990. Effects of antifungal agents on the function of human neutrophils in vitro. Antimicrob Agents Chemother 34:196–201.

    PubMed  CAS  Google Scholar 

  51. Burch PA, Karp JE, Merz MG, Kuhlman JE, Fishman EK. 1987. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol 5:1985–1993.

    PubMed  CAS  Google Scholar 

  52. Horn R, Wong B, Kiehn TE, Armstrong D. 1985. Fungemia in a cancer hospital: Changing frequency, earlier onset, and results of therapy. Rev Infect Dis 7:646–655.

    PubMed  CAS  Google Scholar 

  53. Walsh TJ. 1990. Invasive pulmonary aspergillosis in patients with neoplastic diseases. Semin Respir Infect 5:111–122.

    PubMed  CAS  Google Scholar 

  54. Pannuti CS, Gingrich RD, Pfaller MA, Wenzel RP. 1991. Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: A 9-year study. J Clin Oncol 9:77–84.

    PubMed  CAS  Google Scholar 

  55. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. 1982. Empirical antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72:101–111.

    PubMed  CAS  Google Scholar 

  56. EORTC International Antimicrobial Therapy Cooperative Group. 1989. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 86:668–672.

    Google Scholar 

  57. Ahrens J, Graybill JR, Craven PC, Taylor RL. 1984. Treatment of experimental murine candidiasis with liposome-associated amphotericin B. Sabouraudia 22:163–166.

    PubMed  CAS  Google Scholar 

  58. Juliano RL, Lopez Berestein G, Hopfer R, Mehta R, Mehta K, Mills K. 1985. Selective toxicity and enhanced therapeutic index of liposomal polyene antibiotics in systemic fungal infections. Ann NY Acad Sci 446:390–402.

    PubMed  CAS  Google Scholar 

  59. Sculier JP, Coune A, Meunier F, Brassine C, Laduron C, Hollaert C, Collette N, Heymans C, Klastersky J. 1988. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol 24:527–538.

    PubMed  CAS  Google Scholar 

  60. Szoka FC Jr, Milholland D, Barza M. 1987. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob Agents Chemother 31:421–429.

    PubMed  CAS  Google Scholar 

  61. Mehta T, Lopez-Bernstein G, Hopfer R, Mills K, Juliano RL. 1984. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochem Biophys Acta 770:230–234.

    PubMed  CAS  Google Scholar 

  62. Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta RT, Luna M, Hersh EM, Reuben J, Juliano RL, Bodey GP. 1985. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: A preliminary study. J Infect Dis 151:704–710.

    PubMed  CAS  Google Scholar 

  63. Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, Bonner DP. 1991. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 35:615–621.

    PubMed  CAS  Google Scholar 

  64. Adler-Moore J, Proffitt RT. 1993. Development, characterization, efficacy, and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Liposomal Res 3:429–450.

    CAS  Google Scholar 

  65. Guo LSS, Fielding RM, Mufson D. 1990. Pharmacokinetic study of a novel amphotericin B colloidal dispersion with improved therapeutic index. Ann NY Acad Sci 618:586–588.

    Google Scholar 

  66. Lopez-Berestein et al. 1984.

    Google Scholar 

  67. Gondal et al. 1989.

    Google Scholar 

  68. Proffitt et al. 1991.

    Google Scholar 

  69. Lee JW, Amantea M, Navarro E, Francis P, McManus E, Schaufele R, Bacher J, Pizzo PA, Walsh TJ. 1994. Pharmacokinetics and safety of a unilamellar formulation of liposomal amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 38:713–718.

    PubMed  CAS  Google Scholar 

  70. Sounders et al. 1991.

    Google Scholar 

  71. Fielding RM, Smith PC, Wang LH, Porter J, Guo LSS. 1991. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother 35:1208–1213.

    PubMed  CAS  Google Scholar 

  72. Barwicz et al. 1991.

    Google Scholar 

  73. Francis P, Lee JW, Hoffman A, Peter J, Francesconi A, Bacher J, Shelhamer J, Pizzo PA, Walsh TJ. 1994. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: The potential role of bronchoalveolar lavage D-mannitol and galactomannan as markers of infection. J Infect Dis 169:356–368.

    PubMed  CAS  Google Scholar 

  74. Patterson TF, Miniter P, Dijkstra J, Szoka FC, Jr, Ryan JL, Andriole VT. 1989. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. J Infect Dis 159:717–724.

    PubMed  CAS  Google Scholar 

  75. Allende et al. 1994

    Google Scholar 

  76. Meunier F. 1989. New methods for delivery of antifungal agents. Rev Infect Dis 11 (Suppl 7):s1605–s1612.

    PubMed  CAS  Google Scholar 

  77. Levine SJ, Walsh TJ, Martinez A, Eichacker PQ, Lopez-Berestein G, Natanson C. 1991. Hypoxemia, pulmonary hypertension, and depression of cardiac output as sequelae of liposomal amphotericin B infusion. Ann Intern Med 114:664–666.

    PubMed  CAS  Google Scholar 

  78. Lopez-Berestein G. 1986. Liposomal amphotericin B in the treatment of fungal infections. Ann Intern Med 105:130–131.

    PubMed  CAS  Google Scholar 

  79. Walsh TJ, Hiemenz JW, Seibel N, Anaissie EJ. 1994. Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis. Abstracts of the 34th Interscience Conference on Antimicrobial Agents in Chemotherapy abstract M69, p 247.

    Google Scholar 

  80. Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E, Viviani MA, Gorin NC, Klastersky J, Fenaux P, Prentice HG, Ksionski G. 1991. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 28(Suppl B):63–72.

    Google Scholar 

  81. Tollemar J, Ringden O, Andersson S, et al. 1993. Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: A randomized trial in bone marrow transplant recipients. Transplant Proc 25:1495–1497.

    PubMed  CAS  Google Scholar 

  82. Mehta RT, Hopfer RL, Gunner LA, Juliano RL, Lopez-Berestein G. 1987. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother 31:1897–1900.

    PubMed  CAS  Google Scholar 

  83. Mehta RT, Hopfer RL, McQueen T, Juliano RL, Lopez-Berestein G. 1987. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother 31:1901–1903.

    PubMed  CAS  Google Scholar 

  84. Duschinsky R, Pleven E, Heidelberger C. 1957. The synthesis of 5–fluoropyrimidines. J Am Chem Soc 79:4559–4560.

    CAS  Google Scholar 

  85. Berger J, Duschinsky R. 1962. Control of fungi with 5-fluorocytosine. United States Patent Application Service No. 181, p 822.

    Google Scholar 

  86. Grunberg E, Titsworth E, Bennett M. 1964. Chemotherapeutic activity of 5-fluorocytosine. Antimicrob Agents Chemother 3:566–568.

    Google Scholar 

  87. Medoff et al. 1972.

    Google Scholar 

  88. Francis P, Walsh TJ. 1992. The evolving role of flucytosine in immunocompromised patients: New insights into safety, pharmacokinetics, and antifungal therapy. Rev Infect Dis 15:1003–1018.

    CAS  Google Scholar 

  89. Polak A, Scholer HJ. 1973. Fungistatic activity, uptake and incorporation of 5-fluorocytosine in Candida albicans, as influenced by pyrimidines and purines. II. Studies on distribution and incorporation. Pathol Microbiol 39:334–347.

    CAS  Google Scholar 

  90. Diasio RB, Bennett JE, Myers CE. 1978. Mode of action of 5–fluorocytosine. Biochemi Pharmacol 27:703.

    CAS  Google Scholar 

  91. Polak A, Grenson M. 1973. Evidence for a common transport system for cytosine, adenine and hypoxanthine in Saccharomyces cerevisiae and Candida albicans. Eur J Biochem 32:276–282.

    PubMed  CAS  Google Scholar 

  92. Armstrong D, Schmitt HJ. Older Drugs. 1990. In: Ryley JF, ed Chemotherapy of Fungal Diseases. Berlin: Springer-Verlag, pp 439–454.

    Google Scholar 

  93. Cutler RE, Blair AD, Kelly MR. 1978. Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther 24:333–342.

    PubMed  CAS  Google Scholar 

  94. Schonebeck J, Polak A, Fernex M. 1973. Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function. Chemotherapy 18:321– 326.

    PubMed  CAS  Google Scholar 

  95. Block ER, Bennett JE, Livoti LG, Klein WJ, MacGregor RR, Henderson L. 1974. Flucytosine and amphotericin B: Hemodialysis effects on the plasma concentration and clearance. Ann Intern Med 80:613–617.

    PubMed  CAS  Google Scholar 

  96. Hoeprich 1989.

    Google Scholar 

  97. Bennett JE. 1977. Flucytosine. Ann Intern Med 86:319–322.

    Google Scholar 

  98. Kauffman CA, Frame PT. 1977. Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother 11:244–247.

    PubMed  CAS  Google Scholar 

  99. Diasio RB, Lakings DE, Bennett JE. 1978. Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans. Possible factor in 5-fluorocytosine clinical toxicity. Antimicrob Agents Chemother 14:903–908.

    PubMed  CAS  Google Scholar 

  100. Harris BE, Manning BW, Federle TW. 1986. Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora. Antimicrob Agents Chemother 29:44–48.

    PubMed  CAS  Google Scholar 

  101. Montgomerie JZ, Edwards JE, Guze LB. 1975. Synergism of amphotericin B and 5-fluorocytosine for Candida species. J Infect Dis 132:82–86.

    PubMed  CAS  Google Scholar 

  102. Smego RA, Perfect JR, Durack DT. 1984. Combined therapy with amphotericin B and flucytosine for Candida meningitis. Rev Infect Dis 6:791–801.

    PubMed  Google Scholar 

  103. Thaler M, Bacher J, O’Leary T, Pizzo PA. 1988. An experimental model of candidiasis in rabbits with prolonged neutropenia: Its evaluation of single drug and combination antifungal therapy. J Infect Dis 158:80–88.

    PubMed  CAS  Google Scholar 

  104. Bennett JE, Dismukes WE, Haywood M, Duma RJ, Medoff G, Sande MA, Gallis H, Leonard J, Fields BT, Bradshaw M, Haywood H, McFee ZA, Cate TR, Cobbs CG, Warner JF, Alling DW. 1979. A comparison of amphotericin B alone and in combination with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 301:126–131.

    PubMed  CAS  Google Scholar 

  105. Fujita NK, Reynard M, Sapico FL, Guzel B, Edwards JE. 1981. Cryptococcal intracerebral mass lesions: The role of computer tomography and non-surgical management. Ann Intern Med 94:382–388.

    PubMed  CAS  Google Scholar 

  106. Larsen RA, Leal MA, Chan LS. 1990. Fluconazole compared with amphotericin plus flucytosine for cryptococcal meningitis in AIDS. Ann Intern Med 113:183–187.

    PubMed  CAS  Google Scholar 

  107. Woolley DW. 1944. Some biological effects produced by benzimidazole and their reversal by purines. J Biol Chem 152:225–232.

    CAS  Google Scholar 

  108. van den Bossche H. 1985. Biochemical targets for antifungal azole derivatives: Hypothesis on the mode of action. In: McGinnis M, ed Current Topics in Medical Mycology. New York: Springer-Verlag, pp 313–351.

    Google Scholar 

  109. van den Bossche H, Willemsens G, Cools W, Marichal P, Lauwers W. 1983. Hypothesis on the molecular basis of the antifungal activation of N-substituted imidazoles and triazoles. Biochem Soc Transact 11:665–667.

    Google Scholar 

  110. DeNollin S, Van Belle H, Goossens F, Thone F, Borgers M. 1977. Cytochemical and biochemical studis of yeasts after in vitro exposure to miconazole. Antimicrob Agents Chemother 11:500–513.

    CAS  Google Scholar 

  111. Uno J, Shigematsu ML, Arai T. 1982. Primary site of action of ketoconazole on Candida albicans. Antimicrob Agents Chemother 21:912–918.

    PubMed  CAS  Google Scholar 

  112. Buchel KH, Draber W, Regel E, Plempel M. 1972. Synthesis and properties of clotrimazole and other antimycotic 1-triphenyl-methyl imidazoles. Drugs Made in Germany 15:79–94.

    Google Scholar 

  113. Godefroi EF, Heeres J, VanCutsem J, Janssen PAJ. 1969. The preparation and antimycotic properties of derivatives of 1-phenethylimidazole. J Med Chem 12:784–791.

    PubMed  CAS  Google Scholar 

  114. Holt RJ, Neumann RL. 1972. Laboratory assessment of the antimycotic drug clotrimazole. J Clin Pathol 25:1089–1097.

    PubMed  CAS  Google Scholar 

  115. Heel RC, Brogden RN, Parkes GE, Speight TM, Avery GS. 1980. Miconazole: A preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs 19:7–30.

    PubMed  CAS  Google Scholar 

  116. Fainstein V, Bodey GP. 1980. Cardiorespiratory toxicity due to miconazole. Ann Intern Med 93:432–433.

    PubMed  CAS  Google Scholar 

  117. Wingard JR, Vaughn WP, Braine HG, Merz WG, Sarai R. 1987. Prevention of fungal sepsis in patients with prolonged neutropenia: A randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am J Med 83:1103–1110.

    PubMed  CAS  Google Scholar 

  118. Galgiani JN, Stevens DA, Graybill JR, Stevens DL, Tillinghast AJ, Levine HB. 1984. Pseu-dallescheria boydii infections treated with ketoconazole: Clinical evaluations of seven patients and in vitro susceptibility tests. Chest. 86:219–224.

    PubMed  CAS  Google Scholar 

  119. Van Cutsem J. 1983. The antifungal activity of ketoconazole. Am J Med 74(Suppl 1B):9–15.

    PubMed  Google Scholar 

  120. Daneshmend TK, Warnock DW. 1988. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 14:13–34.

    PubMed  CAS  Google Scholar 

  121. Heel RC, Brgden RN, Carmine A, Morley PA, Speight TM, Avery GS. 1982. Ketoconazole: A review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 23:1–36.

    PubMed  CAS  Google Scholar 

  122. Shadomy S, Espinel-Ingroff A, Tartaglione TA, Dismukes WE, NIAID Mycoses Study Group. 1986. Treatment of systemic mycosis with ketoconazole: Studies of ketoconazole serum levels. Mykosen 29:195–209.

    PubMed  CAS  Google Scholar 

  123. Lelawongs P, Barone JA, Colaizzi JL, Hsuan ATM, Mechlinski W, LeGendre R, Guarnieri J. 1988. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm 7:228–235.

    PubMed  CAS  Google Scholar 

  124. Lake-Bakaar G, Tom W. Lake-Bakaar D, Gupta N, Beidas S, Elsakr M, Straus E. 1988. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome. Ann Intern Med 109:471–473.

    PubMed  CAS  Google Scholar 

  125. Graybill JR. 1989. New antifungal agents. Eur J Clin Microbiol Infect Dis 8:402–412.

    PubMed  CAS  Google Scholar 

  126. Johnson RJ, Blair AD, Ahmad S. 1985. Ketoconazole kinetics in chronic peritoneal dialysis. Clin Pharmacol Therap 37:325–329.

    CAS  Google Scholar 

  127. Dismukes WE, Stamm AM, Graybill JR, Craven PC, Stevens DA, Stiller RL, Sarosi GA, Medoff G, Gregg CR, Gallis HA, Fields Jr, BT, Marier RL, Kerkering TM, Kaplowitz LG, Cloud G, Bowles C, Shadomy S. 1983. Treatment of systemic mycoses with ketoconazole: Emphasis on toxicity and clinical responsiveness. Ann Intern Med 98:13–20.

    PubMed  CAS  Google Scholar 

  128. Sugar AM, Alsip S, Galgiani JN, Graybill JR, Dismukes WE, Cloud GA, Craven PC, Stevens DA. 1987. Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother 31:1874–1878.

    PubMed  CAS  Google Scholar 

  129. Pont A, Graybill JR, Craven PC, Galgiani JN, Dismukes WE, Reitz RE, Stevens DA, the NIAID Mycoses Study Group. 1984. High-dose ketoconazole and adrenal and testicular function in man. Arch Intern Med 144:2150.

    PubMed  CAS  Google Scholar 

  130. Loose DS, Kan PB, Hirst MA, Marcus RA, Feldman D. 1983. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest 71:495–499.

    Google Scholar 

  131. Pont A, Williams PL, Loose DS, Feldman D, Reitz RE, Bochra C, Stevens DA. 1982. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med 97:370–372.

    PubMed  CAS  Google Scholar 

  132. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. 1984. Hepatic injury associated with ketoconazole therapy: Analysis of 33 cases. Gastroenterology 86:503–513.

    PubMed  CAS  Google Scholar 

  133. Shepard JH, Simmons RL. 1986. Cyclosporin-ketoconazole: A potentially dangerous drug interaction. Clin Pharmacol 6:468.

    Google Scholar 

  134. Engelhard D, Stutman HR, Marks MI. 1984. Interaction of ketoconazole with rifampin and isoniazid. N Eng J Med 311:1681–1683.

    CAS  Google Scholar 

  135. Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Potten MR, Richardson MD, Williamson PJ. 1984. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother 25:1–3.

    PubMed  CAS  Google Scholar 

  136. Walsh TJ, Rubin M, Hathorn J, Gress J, Thaler M, et al. 1991. Amphotericin B as. high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. Arch Intern Med 151:765–770.

    PubMed  CAS  Google Scholar 

  137. Ringel SM. 1990. New antifungal agents for the systemic mycoses. Mycopathologia 109:75–87.

    PubMed  CAS  Google Scholar 

  138. Bennett JE. 1990. Antifungal agents. In: Mandell et al., eds Principles and Practice of Infectious Diseases, 3rd ed, pp 361–370, New York: Churchill Livingston.

    Google Scholar 

  139. Grant SM, Clissold SP. 1989. Itraconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37:310–344.

    PubMed  CAS  Google Scholar 

  140. Richardson K, Cooper K, Marriott MS, Tarbit MH, Troke PF, Whittle PJ. 1990. Discovery of fluconazole, a novel antifungal agent. Rev Infect Dis 12(Suppl 3):S267–S271.

    PubMed  CAS  Google Scholar 

  141. Warnock DW. 1989. Itraconazole and fluconazole: New drugs for deep fungal infection. J Antimicrob Chemother 24:275–280.

    PubMed  CAS  Google Scholar 

  142. Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, et al. 1988. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 32:1310–1313.

    PubMed  CAS  Google Scholar 

  143. Tricot G, Joosten E, Boogaerts MA, Van de Pitte J, Cauwenbergh G. 1987. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: Preliminary results of two nonrandomized studies. Rev Infect Dis 9(Suppl l):94–99.

    Google Scholar 

  144. Wishart JM. 1987. The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection. Am Acad Dermatol 220–223.

    Google Scholar 

  145. Heykants J, Michiels M, Meuldermans W, Monbaliu J, Lavrijsen K, Van Peer A, Levron JC, Woestenborghs R, Cauwenbergh G. 1987. The pharmacokinetics of itraconazole in animals and man: An overview. In: Fromtling RA, ed Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Barcelona: JR Prous Science, pp 223–249.

    Google Scholar 

  146. Van Cutsem J, Van Gerven F, Janssen PAJ. 1987. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: Animal models. Rev Infect Dis 9:S15–S32.

    PubMed  Google Scholar 

  147. Boelaert J, Schurgers M, Matthys E, Daneels R, Van Peer A, et al. 1988. Itraconazole pharmacokinetics in patients with renal dysfunction. Antimicrob Agents Chemother 32:1595–1597.

    PubMed  CAS  Google Scholar 

  148. Novakova I, Donnelly P, De Witte T, DePauw B, Boezeman J, et al. 1987. Itraconazole and cyclosporin nephrotoxicity. Lancet 2:920–921.

    PubMed  CAS  Google Scholar 

  149. Trenk D, Brett W, Jahnchen E, Birnbaum D. 1987. Time course of cyclosporine/itraconazole interaction. Lancet 2:1335–1336.

    PubMed  CAS  Google Scholar 

  150. Berenguer J, Ali N, Allende MC, Lee JW, Garrett K, Battaglia S, Rinaldi MG, Pizzo PA, Walsh TJ. 1994. Itraconazole in experimental pulmonary aspergillosis: Comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole plasma concentrations. Antimicrob Agents Chemother 38:1303–1308.

    PubMed  CAS  Google Scholar 

  151. Hay RJ, Clayton YM, Moore MK, Midgely G. 1988. An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol 119:359–366.

    PubMed  CAS  Google Scholar 

  152. Graybill JR. 1990. Systemic azole antifungal drugs—into the 1990s. In: Ryley JF, ed Chemotherapy of Fungal Diseases. Berlin: Springer-Verlag, pp 453–482.

    Google Scholar 

  153. Cauwenbergh G, DeDoncker P, Stoops K, DeDier AM, Goyvaerts H, Schuermans V. 1987. Itraconazole in the treatment of human mycoses: Review of three years of clinical experience. Rev Infect Dis 9(Suppl 1):S146–S152.

    PubMed  Google Scholar 

  154. Sharkey PK, Rinaldi MG, Lerner C, Fetchick R, Dunn JF, Graybill JR. 1988. High dose itraconazole in the treatment of severe mycoses. 28th Interscience Conference of Antimicrobial Agents and Chemotherapy, abstract 575, Los Angeles.

    Google Scholar 

  155. Dupont B, Drouhet, E. 1988. The treatment of aspergillosis with azole derivatives. In: Van den Bossche H, Mackenzie DWR, Cauwenbergh G, eds Aspergillus and Aspergillosis. New York: Plenum, pp 243–251.

    Google Scholar 

  156. Denning DW, Tucker RM, Hanson LH, Stevens DA. 1989. Treatment of invasive aspergillosis with itraconazole. Am J Med 86:791–800.

    PubMed  CAS  Google Scholar 

  157. Viviani MA, Tortorano AM, Pagano A, et al. 1990. European experience with itraconazole in systemic mycoses. J Am Acad Dermatol 23:587–593.

    PubMed  CAS  Google Scholar 

  158. Denning DW, Stevens DA. 1991. Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 35:1329–1333.

    PubMed  CAS  Google Scholar 

  159. Vreugdenhil G, Van Dijke BJ, Donnelly JP, Novakova IRO, Raemaekers JMM, Hoogkamp-Korstanje MAA, De Pauw BE. 1993. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematological malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 11:353–358.

    PubMed  CAS  Google Scholar 

  160. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, DeBeule K. 1989. Antifungal prophylaxis with itraconazole in prolonged neutropenia: Correlation with plasma levels. Mycoses 32(Suppl 1): 103–108.

    PubMed  Google Scholar 

  161. Ganer A, Arathoon E, Stevens DA. 1987. Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole. Rev Infect Dis 9:S77–S86.

    PubMed  Google Scholar 

  162. Sharkey K, Graybill JR, Rinaldi MG, et al. 1990. Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol 23:577–586.

    PubMed  CAS  Google Scholar 

  163. Negroni R, Palmierei O, Koren F, Tiraboschi IN, Galimberti RL. 1987. Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans. Rev Infect Dis 9:S47–S50.

    PubMed  Google Scholar 

  164. Philips P, Fetchick R, Weisman I, Foshee S, Graybill JR. 1987. Tolerance to and efficacy of itraconazole in treatment of systemic mycoses: Preliminary results. Rev Infect Dis 9:S87–S93.

    Google Scholar 

  165. Wheat LJ, Hafner RE, Wulfsohn M, Johnson J, Owens S. 1991. Itraconazole is effective maintenance treatment for prevention of relapse of histoplasmosis in AIDS: Prospective multicenter non-comparative trial.

    Google Scholar 

  166. Shaw JTB, Tarbit MH, Troke PF. 1987. Cytochrome P-450 mediated sterol synthesis and metabolism: Differences in sensitivity to fluconazole and other azoles. In: Fromtling RA, eds Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Barcelona: JR Prous, pp 125–139.

    Google Scholar 

  167. Galgiani JN. 1987. Antifungal susceptibility tests. Antimicrob Agents Chemother 31:1867–1870.

    PubMed  CAS  Google Scholar 

  168. National Committee for Clinical Laboratory Standards. 1992. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed Standard. NCCLS document M27–P. Villanova, PA: NCCLS.

    Google Scholar 

  169. Pfaller MA, Dupont B, Kobayashi GS, Muller J, Rinaldi MG, Shadomy S, Troke PF, Walsh TJ, Warnock DW. 1992. Standardized susceptibility testing of fluconazole: An international collaborative study. Antimicrob Agents Chemother 36:1805–1809.

    PubMed  CAS  Google Scholar 

  170. Humphrey MJ, Jevons S, Tarbit MH. 1985. Pharmacokinetic evaluation of UK-49, 858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 28:648–653.

    PubMed  CAS  Google Scholar 

  171. Brammer KW, Farrow PR, Faulkner JK. 1990. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 12(Suppl 3):S318–S326.

    PubMed  Google Scholar 

  172. Drew RH, Perfect JR, Gallis HE. 1988. Use of fluconazole in a patient with documented malabsorption of ketoconazole. Clin Pharm 7:622–623.

    PubMed  CAS  Google Scholar 

  173. Foulds G, Wajszczuk C, Weidler DJ, Garg DC, Gibson P. 1987. Steady state parenteral kinetics of fluconazole in man. 1st International Conference on Drug Research and Immunologic Infectious Diseases, abstract P-6.

    Google Scholar 

  174. Shiba K, Saito A, Miyahara T. 1989. Pharmacokinetic evaluation of fluconazole in healthy volunteers. Jpn J Antibiot 42:17–30.

    PubMed  CAS  Google Scholar 

  175. Brammer KW, Tarbit MH. 1987. A review of the pharmacokinetics of fluconazole (UK-49, 858) in laboratory animals and man. In: Fromtling RA, ed Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Barcelona: JR Prous Science, pp 141–149.

    Google Scholar 

  176. Lee JW, Seibel NI, Amantea MA, Whitcomb P, Pizzo PA, Walsh TJ. 1992. Safety, tolerance, and pharmacokinetics of fluconazole in children with neoplastic diseases J Pediatr 120:987–993.

    PubMed  CAS  Google Scholar 

  177. Ebden P, Neill P, Farrow PR. 1989. Sputum levels of fluconazole in humans. Antimicrob Agents Chemother 33:963–964.

    PubMed  CAS  Google Scholar 

  178. Savani DV, Perfect JR, Cobo LM, Durack DT. 1987. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother 31:6–10.

    PubMed  CAS  Google Scholar 

  179. Walsh, TJ, Foulds G, Pizzo PA. 1989. Pharmacokinetics and tissue penetration of fluconazole in rabbits. Antimicrobial Agents Chemother 33:467–469.

    CAS  Google Scholar 

  180. Perfect JR, Durack DT. 1985. Penetration of imidazoles and triazoles into cerebrospinal fluid in rabbits. J Antimicrob Chemother 16:81–86.

    PubMed  CAS  Google Scholar 

  181. Arndt CAS, Walsh TJ, McCully CL, Balis FM, Pizzo PA, Poplack DG. 1988. Fluconazole penetration into cerebrospinal fluid: Implications for treating fungal infections of the central nervous system. J Infect Dis 157:178–180.

    PubMed  CAS  Google Scholar 

  182. Foulds G, Brennan DR, Wajszczuk C, Catanzaro A, Carg DC, Knopf W, Rinaldi M, Weidler DJ. 1988, Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol 28:363–366.

    PubMed  CAS  Google Scholar 

  183. Tucker RM, Williams PL, Arathoon EG, Levine BE, Hartstein AI, Hanson LH, Stevens DA. 1988. Pharmacokinetics of fluconazole in cerbrospinal fluid and serum in human coccidioidal meningitis. Antimicrob Agents Chemother 32:369–373.

    PubMed  CAS  Google Scholar 

  184. Grant SM, Clissold SP. 1990. Fluconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39:877–916.

    PubMed  CAS  Google Scholar 

  185. Saag MS, Dismukes WE. 1988. Azole antifungal agents: Emphasis on new triazoles. Antimicrob Agents Chemother 32:1–8.

    PubMed  CAS  Google Scholar 

  186. Tachibana M, Noguchi Y, Monro AM. 1987. Toxicology of fluconazole in experimental animals. In: Fromtling RA, ed Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Barcelona: JR Prous, pp 93–102.

    Google Scholar 

  187. Mitchell AS, Holland JT. 1989. Fluconazole and phenytoin: A predictable interaction. Bri Med J 298:1315.

    CAS  Google Scholar 

  188. Lazar JD, Wilner KD. 1990. Drug interactions with fluconazole. Rev Infect Dis 12(Suppl 3):S327–S333.

    PubMed  CAS  Google Scholar 

  189. Walsh, TJ, Lee J, Aoki S, Mechinaud F, Bacher J, Lecciones J, Thomas V, Rubin M, Pizzo PA. 1990. Experimental basis for use of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts. Rev Infect Dis 12(Suppl 3):S307–S317.

    PubMed  CAS  Google Scholar 

  190. Goodman J, Buell D, Gilbert G, for the Seventeen Member Marrow Transplant Study Group. 1991. Fluconazole prevents fungal infections in bone marrow transplantation: Results of a placebo-controlled, double blind, randomized multicenter trial. Program and Abstracts of the XI Congress of the International Society for Human and Animal Mycology, Montreal. Abstract no. p S3114.

    Google Scholar 

  191. Slavin M, Bowden R, Osborne B, Adams R, Levenstein M, Feldman A, Meyers J. 1992. Fluconazole prophylaxis in marrow transplant recipients. Program and Abstracts of the 1992 Interscience Conference on Antimicrobial Agents in Chemotherapy. American Society for Microbiology, Washington DC, abstract no. 623, p 214.

    Google Scholar 

  192. Winston DJ, Chandrashekar, Lazarus HM, et al. 1993. Fluconazole prophylaxis of fungal infections in patients with leukemia. Ann Intern Med 118:495–503.

    PubMed  CAS  Google Scholar 

  193. Anaissie E, Reuben A, Cunningham K, Bodey GP. 1990. Randomized trial of fluconazole vs. intravenous amphotericin B for antifungal prophylaxis in neutropenic patients with leukemia. Program and Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, GA, October, Abstract no. 572, p 21.

    Google Scholar 

  194. Wingard JR, Merz, Rinaldi MG, Johnson TR, Karp JE, Sarai R. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325:12740–1277.

    Google Scholar 

  195. Persons PA, Laughlin M, Tanner D, Perfect J, Guckerman JP, Hathorn JW. 1991. Fluconazole and Candida krusei fungemia. N Engl J Med 325:1315.

    PubMed  CAS  Google Scholar 

  196. Tarn JY, Blume KG, Prober CG. 1992. Prophylactic fluconazole and Candida krusei infections [letter]. N Engl J Med 326:891.

    Google Scholar 

  197. Gondal et al. 1989 on p 234 in text.

    Google Scholar 

  198. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheid WM, Karchmer AW, Dine AP, Levenstein MJ, and Webb CD. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 331:1325–1330.

    PubMed  CAS  Google Scholar 

  199. Sugar AM, Saunders C. 1988. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med 85:481–489.

    PubMed  CAS  Google Scholar 

  200. Bozzette SA, Larsen RA, Chiu J, et al. 1991. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med 324:580–584.

    PubMed  CAS  Google Scholar 

  201. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, et al. 1992. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 326:83–89.

    PubMed  CAS  Google Scholar 

  202. Tucker RM, Galgiani JN, Denning DW, Hanson LH, Graybill JR, Sharkey K, Eckman MR, Salemi C, Libke R, Klein RA, Stevens DA. 1990. Treatment of coccidioidal meningitis with fluconazole. Rev Infect Dis 12(Suppl 3):S380–S389.

    PubMed  Google Scholar 

  203. Kauffman CA, Bradley SF, Ross SC, Weber DR. 1991. Hepatosplenic candidiasis: Successful treatment with fluconazole. Am J Med 91:137–141.

    PubMed  CAS  Google Scholar 

  204. Anaissie E, Bodey GP, Kantarjian H, David C, Barnett K, Bow E, Defelice R, Downs N, File T, Karam G, Potts D, Shelton M, Sugar A. 1991. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 91:142–150.

    PubMed  CAS  Google Scholar 

  205. Ryley JF, McGregor S, Wilson RG. 1988. Activity of ICI 195,739—a novel, orally active bistriazole—in rodent models of fungal and protozoal infections. Ann NY Acad Sci 544:310–328.

    PubMed  CAS  Google Scholar 

  206. Fromtling RA. 1988. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev 1:187–217.

    PubMed  CAS  Google Scholar 

  207. Tucker RM, Hanson LH, Brummer E, Stevens DA. 1989. Activity of ICI 195,739, a new oral triazole, compared with that of ketoconazole in the therapy of experimental murine blastomycosis. Antimicrob Agents Chemother 33:573–575.

    PubMed  CAS  Google Scholar 

  208. Barchiesi F, Colombo AL, McGough DA, Fothergill AW, Rinaldi MG. 1994. In vitro activity of DO870 against Candida albicans and Aspergillus spp. Abstracts of the 34th Interscience onference on Antimicrobial Agents in Chemotherapy. Orlando, Florida, October 4–7, 1994, abstract F199, p 255.

    Google Scholar 

  209. Najvar L, Bocanegra R, Luther M, Graybill J. 1994. Abstracts of the 34th Interscience Conference on Antimicrobial Agents in Chemotherapy. Orlando, Florida, October 4–7, abstract F201, p 255.

    Google Scholar 

  210. Lee JW, Lin C, Loebenberg D, Rubin M, Pizzo PA, Walsh TJ. 1989. Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits. Antimicrob Agents Chemother 33:1932–1935.

    PubMed  CAS  Google Scholar 

  211. Perfect JR, Wright KA, Hobbs MM, Durack DT. 1989. Treatment of experimental cryptococcal meningitis and disseminated candidiasis with Sch 39304. Antimicrob Agents Chemother 33:1735–1740.

    PubMed  CAS  Google Scholar 

  212. Restrepo BI, Ahrens J, Graybill JR. 1989. Efficacy of Sch 39304 in murine cryptococcosis. Antimicrob Agents Chemother 33:1242–1246.

    PubMed  CAS  Google Scholar 

  213. Walsh TJ, Lester-McCully C, Rinaldi MG, Wallace JE, Balis FM, Lee JW, Pizzo PA, Poplack DG. 1990. Penetration of Sch 39304, a new triazole, into cerebrospinal fluid of primates. Antimicrob Agents Chemother 34:1281–1284.

    PubMed  CAS  Google Scholar 

  214. Lin C, Kim H, Lapiguera A, Loebenberg D, Miller GH, Symchowicz S. 1988. Comparative pharmacokinetics of Sch 39304 and fluconazole in mice, rabbits, S. monkeys, and C. monkeys. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles. Abstract no. 163.

    Google Scholar 

  215. Walsh TJ, Lee JW, Lecciones J, Kelly P, Peter J, Thomas V, Bacher J, Pizzo PA. 1990. Sch 39304 in prevention and treatment of disseminated candidiasis in persistently granulocytopenic rabbits. Antimicrob Agents Chemother 34:1560–1564.

    PubMed  CAS  Google Scholar 

  216. Albert MM, Graybill JR, Rinaldi MG. 1991. Treatment of murine cryptococcal meningitis with an SCH 39304–amphotericin B combination. Antimicrob Agents Chemother 35:1721–1725.

    PubMed  CAS  Google Scholar 

  217. Anaissie EJ, Kontoyiannis DP, Vartivarian S, Kantarjian HM, et al. 1993. Effectiveness of an oral triazole for opportunistic mold infections in patient with cancer: Experience with SCH393904. Clin Infect Dis 17:1022–1031.

    PubMed  CAS  Google Scholar 

  218. Van Cutsem J, Van Gerven F, Janssen PAJ. 1988. R66905, a new potent broad-spectrum antifungal with topical, oral and parenteral activity. Rev Iberica Micologia 5(Suppl 1):Abstract 0–2.

    Google Scholar 

  219. Van Cutsem J, Van Gerven F, Janssen PAJ. 1989. Oral and parenteral therapy with saperconazole (R66905) of invasive aspergillosis in normal and immunocompromised animals. Antimicrob Agents Chemother 33:2063–2068.

    PubMed  Google Scholar 

  220. Van Cutsem J, Van Gerven F, Janssen PAJ. 1989. Saperconazole, a new potent antifungal triazole: In vitro activity spectrum and therapeutic efficacy. Drugs Future 14:1187–1209.

    Google Scholar 

  221. Sawistowska-Schroder ET, Kerridge D, Perry H. 1984. Echinocandin inhibition of 1,3-b-D-glucan synthase from Candida albicans. Fed Eur Biochem Soc Lett 173:134–138.

    CAS  Google Scholar 

  222. Debono M, Abbott BJ, Turner JR, Howard LC, Gordee RS, Hunt AS, Barnhart M, Molloy RM, Willard KE, Fukuda DS, Butler TF, Zeckner DJ. 1988. Synthesis and evaluation of LY121019, a member of a series of semi-synthetic analogues of the antifungal lipopeptide echinocandin B. Ann NY Acad Sci 544:152–167.

    PubMed  CAS  Google Scholar 

  223. Gordee RS, Zechner DJ, Ellis LF, Thakker AL, Howard LC. 1984. In vitro and in vivo anti-Candida activity and toxicology of LY121019. J Antibiot 37:1054–1065.

    PubMed  CAS  Google Scholar 

  224. Gordee RS, Zeckner DJ, Howard LC, Alborn WE, Debono M. 1988. Anti-Candida activity and toxicology of LY121019, a novel semisynthetic polypeptide antifungal antibiotic. Ann NY Acad Sci 544:294–309.

    PubMed  CAS  Google Scholar 

  225. Pfaller M, Riley J, Koerner T. 1989. Effects of cilofungin LY121019 on carbohydrate and sterol composition of Candida albicans. Eur J Clin Microbiol Infect Dis 8:1067–1070.

    PubMed  CAS  Google Scholar 

  226. Hobbs M, Perfect JR, Durack D. 1988. Evaluation of in vitro antifungal activity of LY121019. Eur J Clin Microbiol Infect Dis 7:77–80.

    PubMed  CAS  Google Scholar 

  227. Melchinger W, Mueller J. 1987. Studies of the in vitro sensitivity of yeast strains isolated from clinical specimens to LY121019, a new antifungal agent. Mykosen 30:605–608.

    PubMed  CAS  Google Scholar 

  228. Schmatz DM, Romancheck MA, Pittarelli LA, Schwartz RE, Fromtling RA, Nollstadt KH, Vanmiddlesworth FL, Wilson, KE, Turner MJ. 1990. Treatment of Pneumocystis carinii pneumonia with 1,3-b-glucan synthesis inhibitors. Proc Nat Acad Med 87:5950–5954.

    CAS  Google Scholar 

  229. Black HR, Brier GL, Wolny JD, Dorrbecker SH. 1989. Pharmacology and pharmacokinetics of cilofungin. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract no. 1357, Houston.

    Google Scholar 

  230. Lee JW, Kelly P, Lecciones J, Coleman D, Gordee R, Pizzo PA, Walsh TJ. 1990. Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits. Antimicrob Agents Chemother 34:2240–2245.

    PubMed  CAS  Google Scholar 

  231. Walsh TJ, Lee JW, Kelly P, Bacher J, Lecciones J, Thomas V, Lyman C, Coleman D, Gordee R, Pizzo PA. 1991. Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-β-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis. Antimicrobial Agents Chemother 35:1321–1328.

    CAS  Google Scholar 

  232. Balkovec JM, Black RM, Hammond ML, Heck JV, Zambias RA, Abruzzo G, Bartizal K, Puckett J, Trainor C, Schwartz R, McFadden DC, Nollstadt K, Pittarelli LA, Powles MA, Schmatz DM. 1991. Echinocandin analogues: Synthesis and in vivo efficacy of L-693,989 and other water soluble echinocandins in Candida and Pneumocystis rodent models. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, abstract no. 204.

    Google Scholar 

  233. Bartizal K, Abruzzo G, Trainor C, Puckett J, Ponticas S, Krupa D, Schmatz D, Nollstadt K, Schwartz R, Hammond M, Balkovec, J, Zambias R, Kropp H. 1991. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, abstract no. 206.

    Google Scholar 

  234. Hajdu R, Sundelof JG, Bartizal K, Abruzzo G, Trainor C, Thompson R, Kropp H. 1991. Comparative pharmacokinetics in four animal species of L-688,786 and its water soluble prodrug, L-693,989. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, abstract 209.

    Google Scholar 

  235. Suzuki S, Isono K, Nagutsu J, Mizutani T, Kawashimer C, Mizuno T. 1965. A new antibiotic, polyoxin A. J Antibiot 18:131–132.

    PubMed  CAS  Google Scholar 

  236. Fiedler HP, Kurth R, Langharig J, Delzer J, Zahner H. 1982. Nikkomycins: Microbial inhibitors of chitin synthetase. J Chem Biotechnol 32:271–280.

    CAS  Google Scholar 

  237. Isono K, Nagatsu J, Kawashiwa Y, Suzuki S. 1985. Studies on polyoxins, antifungal antibiotics. I. Isolation and characterization of polyoxins A and B. Agricult Biolog Chem 29:848–854.

    Google Scholar 

  238. Gooday GW. 1988. Chitin metabolism: A target for antifungal and antiparasitic drugs. In: Borowski E, Shugar D, eds Molecular Aspects of Chemotherapy. New York: Pergamon Press, pp 175–185.

    Google Scholar 

  239. Payne JW, Shallow DA. 1985. Studies on drug targeting in the pathogenic fungus Candida albicans: Peptide transport mutants resistant to polyoxins, nikkomycins, and bacilysin. Fed Eur Microbiol Soc Microbiol Lett 28:55–60.

    CAS  Google Scholar 

  240. Hector RF, Zimmer BL, Pappagianis D. 1990. Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis. Antimicrob Agents Chemother 34:587–593.

    PubMed  CAS  Google Scholar 

  241. Smith et al. 1986.

    Google Scholar 

  242. Novider et al. 1983.

    Google Scholar 

  243. Petranyi G, Ryer NS, Stutz A. 1984. Allylamine derivatives: New class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 224:1239–1241.

    PubMed  CAS  Google Scholar 

  244. Shadomy S, Espinel-Ingroff A, Gebhart RJ. 1985. In vitro studies with SF 86–327, a new orally active allylamine derivative. Sabouraudia 23:125–132.

    PubMed  CAS  Google Scholar 

  245. Smith EB. 1990. History of antifungals. J Am Acad Dermatol 23:776–778.

    PubMed  CAS  Google Scholar 

  246. Ryder & Dupont 1985.

    Google Scholar 

  247. Villard V, Jones T. 1989. Clinical efficacy and tolerability of terbinafine (Lamisil)—a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol 14:124–127.

    Google Scholar 

  248. Petranyi G, Meingassner JG, Mieth H. 1987. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother 31:1365–1368.

    PubMed  CAS  Google Scholar 

  249. Jones TC, Villars VV. 1990. Terbinafine. In: Ryley JF, ed Chemotherapy of Fungal Diseases. Berlin: Springer-Verlag pp 483–503.

    Google Scholar 

  250. Oki T, Konishi M, Tomatsu K, Tomita K, Saitoh, Tsunakawa M, Nishio M, Miyaki T, Kawaguchi H. 1988. Pradimicin, a novel class of potent antifungal antibiotics. J Antibiot 41:1701–1704.

    PubMed  CAS  Google Scholar 

  251. Tsunakawa M, Nishio M, Ohkuma H, Tsuno T, Konishi M, Naito T, Oki T, Dawaguchi H. 1988. A new antifungal antibiotic, BMY-28567. Structure elucidation. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, abstract 1001.

    Google Scholar 

  252. Takeuchi T, Hara T, Naganawa H, Okada M, Hamada M, Umezawa H, Gomi S, Sezaki M, Kondo S. 1988. New antifungal antibiotics, benanomicins A and B from an Actinomycete. J Antibiot 41:807–811.

    PubMed  CAS  Google Scholar 

  253. Oki T, Saitoh K, Tomatsu K, Tomita K, Konishi M, Kawaguchi H. 1988. Novel antifungal antibiotic BMY-28567. Ann NY Acad Sci 544:184–187.

    PubMed  CAS  Google Scholar 

  254. Oki T, Tenmyo O, Hirano M, Tomatsu K, Kamei H. 1990. Pradimicins A, B and C: New antifungal antibiotics. II. In vitro and in vivo biological activities. J Antibiot 43:763–770.

    Google Scholar 

  255. Walsh TJ, van Cutsem J, Polak A, Graybill JR. 1992. Pathogenesis, immunomodulation, and antifungal therapy of experimental invasive candidiasis, histoplasmosis, and aspergillosis: Recent advances and concepts. J Med Vet Mycol 30(Suppl l):225–240.

    PubMed  Google Scholar 

  256. Roilides 1994.

    Google Scholar 

  257. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. 1993. Role of granulocyte-macrophage colony stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 17:705–707.

    PubMed  CAS  Google Scholar 

  258. Neumanaitis J, Mayers JD, Buckner CD, et al. 1991. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 4:907–913.

    Google Scholar 

  259. Anaissie E. 1992. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and review. Clin Infect Dis 14(Suppl 1):S43–S53.

    PubMed  Google Scholar 

  260. Denning DW, Pappas PG, Kauffman CA, Hostetier JS, Lee JY, Stevens DA. 1991. Oral itraconazole therapy of invasive aspergillosis. 31st Interscientific Conference on Antimicrobial Agents and Chemotherapy, Chicago, abstract no. 1158.

    Google Scholar 

  261. Lee JW, Seibel NL, Amantea M, Whitcomb P, Pizzo PA, Walsh TJ. 1991. Safety, tolerance, and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr, xx:xxx-xxx.

    Google Scholar 

  262. Nair MG, Putnam AR, Mishra SK, Mulks MH, Taft WH, Keller JE, Miller JR, Zhu PP, Meinhart JD, Lynn DG. 1989. Faeriefungin: A new broad-spectrum antibiotic from Streptomyces griseus var. autotrophicus. J Nat Prod 52:797–809.

    PubMed  CAS  Google Scholar 

  263. Mulks MH, Nair MG, Putnam AR. 1990. In vitro antibacterial activity of faeriefungin, a new broad-spectrum polyene macrolide antibiotic. Antimicrob Agents Chemother 34:1762–1765.

    PubMed  CAS  Google Scholar 

  264. Roilides E, Pizzo PA. 1992. Modulation of host defenses by cytokines: Evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. 15:508–523.

    Google Scholar 

  265. Ryder NS. 1988. Biochemical mode of action and enantiomeric selectivity of SDZ 89–485. Rev Iberica Micologia 5(Suppl l):Abst. P-154.

    Google Scholar 

  266. Steele RW, Abernathy RS. 1983. Systemic blastomycosis in children. Pediatr Infect Dis J 2:304–307.

    CAS  Google Scholar 

  267. Thaler M, Hathorn J, Skelton J, Rubin M, McKnight J, Pastakia R, Shawker T, Pizzo PA. 1988. Hepatic candidiasis in cancer patients. Ann Intern Med 108:88–100.

    PubMed  CAS  Google Scholar 

  268. Van Cauteren H, Heykants J, DeCoster R, Cauwenbergh G. 1987. Itraconazole: Pharmacologic studies in animals and humans. Rev Infect Dis 9:S43–S46.

    PubMed  Google Scholar 

Download references

Authors
  1. Thomas J. Walsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caron A. Lyman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Service de Medecine Interne et Laboratoire d’Inverstigation, Clinique, H.J. Tagnon, Institut Jules Bordet, Centre des Tumeurs de L’Universite, Libre de Bruxelles, Belgium

    Jean Klastersky

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Kluwer Academic Publishers

About this chapter

Cite this chapter

Walsh, T.J., Lyman, C.A. (1995). New antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseases. In: Klastersky, J. (eds) Infectious Complications of Cancer. Cancer Treatment and Research, vol 79. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1239-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1239-0_6

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8527-4

  • Online ISBN: 978-1-4613-1239-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation